References:
1. Hunger, S.P., et al.,Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol, 2012. 30 (14): p. 1663-9.
2. Pui, C.H., et al., Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol, 2015. 33 (27): p. 2938-48.
3. Steinherz, P.G., et al.,Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children’s Cancer Group.Cancer, 1998. 82 (3): p. 600-12.
4. Uckun, F.M., et al., Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.Blood, 1998. 91 (3): p. 735-46.
5. Teachey, D.T. and D. O’Connor,How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood, 2020.135 (3): p. 159-166.
6. Jeha, S., et al., Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol, 2019.37 (35): p. 3377-3391.
7. Quist-Paulsen, P., et al.,T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 2020.34 (2): p. 347-357.
8. Hofmans, M., et al., Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL). Br J Haematol, 2019.186 (5): p. 741-753.
9. Moricke, A., et al.,Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016.127 (17): p. 2101-12.
10. Place, A.E., et al.,Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol, 2015. 16 (16): p. 1677-90.
11. Pui, C.H., et al., Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med, 2009. 360 (26): p. 2730-41.
12. 2014, P.A.A.M.A.
13. Winter SS blood 2015, A.
14. Madanat, F., et al.,Features and outcomes of pediatric early T cell leukemia: King Hussein Cancer Center experience. Hematol Oncol Stem Cell Ther, 2016.9 (3): p. 126-8.
15. Vilmer, E., et al.,Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia, 2000. 14 (12): p. 2257-66.
16. Nachman, J.B., et al.,Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med, 1998. 338 (23): p. 1663-71.
17. Parker, C., et al.,Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematol, 2019. 6 (4): p. e204-e216.
18. Parker, C., et al., Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.Lancet, 2010. 376 (9757): p. 2009-17.
19. Conter, V., et al., Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.Lancet Haematol, 2016. 3 (2): p. e80-6.
20. Vora, A., et al., Improved outcome for children and young adults with T-cell acute lymphoblastic leukaemia (ALL): results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003. Blood, 2008. 112 (11): p. 908.
21. Place, A.E., et al.,Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001 , 2014, American Society of Clinical Oncology.
22. Vora, A., et al., Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol, 2014. 15 (8): p. 809-18.
23. Vora, A., et al., Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol, 2013.14 (3): p. 199-209.
24. Kelly, M.J., et al.,Cranial radiation for pediatric T-lineage acute lymphoblastic leukemia: a systematic review and meta-analysis. Am J Hematol, 2014.89 (10): p. 992-7.
25. De Moerloose, B., et al.,Low CNS relapse incidence without radiotherapy and improvement of outcome: results of subsequent EORTC-CLG 58881 and 58951 trials in pediatric T-cell acute lymphoblastic leukemia (ALL) , 2012, American Society of Hematology.
26. Vora, A.J., et al., UKALL 2003, a randomised trial investigating treatment intensification for children and young adults with minimal residual disease defined high risk acute lymphoblastic leukaema , 2012, American Society of Hematology.
27. Patrick, K., et al.,Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol, 2014. 166 (3): p. 421-4.
28. Dunsmore, K.P., et al.,Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol, 2020. 38 (28): p. 3282-3293.
29. Winter, S.S., et al., Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0434. Pediatr Blood Cancer, 2015. 62 (7): p. 1176-83.
30. Dunsmore, K.P., et al.,Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol, 2012.30 (22): p. 2753-9.